Table 1 Baseline demographic and clinical characteristics of all participants.
Grouped by interquartile of MWSS | Grouped by interquartile of PWSS | |||||
---|---|---|---|---|---|---|
Q1+2+3 group (n = 1081) | Q4 group (n = 366) | p value | Q1+2+3 group (n = 1085) | Q4 group (n = 362) | p value | |
Clinical parameters | ||||||
Age (years) | 68.08 ± 5.72 | 67.44 ± 5.03 | 0.055 | 68.06 ± 5.69 | 67.49 ± 5.14 | 0.094 |
Female [n (%)] | 543 (50.2) | 181 (49.5) | 0.797 | 543 (50.0) | 181 (50.0) | 0.988 |
Smoking [n (%)] | 241 (22.3) | 85 (23.2) | 0.713 | 253 (23.3) | 73 (20.2) | 0.214 |
Alcohol intake [n (%)] | 382 (35.3) | 153 (41.8) | 0.034 | 392 (36.1) | 143 (39.5) | 0.288 |
Hypertension [n (%)] | 759 (70.2) | 183 (50.0) | <0.001 | 744 (68.6) | 198 (54.7) | <0.001 |
Antihypertensive medication [n (%)] | 684 (90.1) | 168 (91.8) | 0.486 | 673 (90.4) | 179 (90.4) | 0.982 |
Diabetes [n (%)] | 127 (11.7) | 44 (12.0) | 0.889 | 123 (11.3) | 48 (13.3) | 0.326 |
Lowering-glucose medication [n (%)] | 120 (94.5) | 42 (95.5) | 0.805 | 116 (94.3) | 46 (95.8) | 0.688 |
Dyslipidemia [n (%)] | 286 (26.5) | 117 (32.0) | 0.042 | 285 (26.3) | 118 (32.6) | 0.020 |
Antidyslipidemia medication [n (%)] | 140 (49.0) | 59 (50.4) | 0.788 | 142 (49.8) | 57 (48.3) | 0.781 |
Antiplatelet medication [n (%)] | 307 (28.4) | 92 (25.1) | 0.227 | 297 (27.4) | 102 (28.2) | 0.767 |
Body mass index (kg/m2) | 24.06 ± 2.86 | 23.89 ± 2.61 | 0.311 | 23.96 ± 2.86 | 24.21 ± 2.61 | 0.128 |
SBP (mm Hg) | 141.21 ± 13.50 | 138.11 ± 13.33 | <0.001 | 141.01 ± 13.12 | 138.58 ± 14.54 | 0.003 |
DBP (mm Hg) | 70.49 ± 7.07 | 70.28 ± 7.06 | 0.619 | 70.58 ± 7.00 | 70.01 ± 7.26 | 0.188 |
Biochemical parameters | ||||||
Total cholesterol (mmol/L) | 4.65 ± 0.89 | 4.65 ± 0.97 | 0.956 | 4.62 ± 0.90 | 4.74 ± 0.93 | 0.037 |
Triglycerides (mmol/L) | 1.58 ± 0.57 | 1.63 ± 0.53 | 0.118 | 1.59 ± 0.56 | 1.60 ± 0.54 | 0.712 |
HDL-c (mmol/L) | 1.14 ± 0.47 | 1.16 ± 0.51 | 0.467 | 1.13 ± 0.47 | 1.21 ± 0.50 | 0.003 |
LDL-c (mmol/L) | 2.79 ± 0.72 | 2.75 ± 0.83 | 0.360 | 2.77 ± 0.73 | 2.80 ± 0.81 | 0.610 |
FPG (mmol/L) | 5.37 (4.65, 6.22) | 5.23 (4.48, 6.06) | 0.005 | 5.29 (4.59, 6.16) | 5.44 (4.66, 6.20) | 0.056 |
Creatinine (mg/dL) | 0.83 ± 0.19 | 0.70 ± 0.14 | <0.001 | 0.82 ± 0.19 | 0.74 ± 0.17 | <0.001 |
Cystatin C (mg/L) | 0.97 (0.83, 1.16) | 0.79 (0.64, 0.93) | <0.001 | 0.94 (0.82, 1.14) | 0.84 (0.70, 1.01) | <0.001 |
Urinary albumin (mg/L) | 1.52 (0.99, 2.21) | 0.79 (0.55, 1.12) | <0.001 | 1.41 (0.89, 2.08) | 0.93 (0.68, 1.46) | <0.001 |
Endothelial functional and inflammatory parameters | ||||||
NO (μmol/L) | 50.52 (59.93, 68.49) | 76.52 (68.70, 85.52) | <0.001 | 61.03 (51.05, 70.89) | 73.09 (63.07, 81.96) | <0.001 |
ET-1 (pg/mL) | 78.86 (69.29, 87.56) | 75.40 (67.58, 84.09) | <0.001 | 76.99 (67.85, 85.76) | 80.05 (72.87, 88.27) | <0.001 |
ICAM-1 (ng/mL) | 137.3 (117.2, 171.0) | 134.9 (122.2, 148.8) | 0.034 | 139.1 (119.1, 172.1) | 133.2 (117.0, 146.8) | 0.001 |
VCAM-1 (ng/mL) | 644.3 (581.9, 732.0) | 618.6 (552.4, 688.6) | <0.001 | 644.3 (575.2, 727.6) | 613.8 (556.1, 702.9) | <0.001 |
hsCRP (mg/L) | 3.58 (3.02, 4.20) | 2.93 (2.48, 3.57) | <0.001 | 3.53 (2.93, 4.12) | 3.15 (2.65, 3.70) | <0.001 |
CCA ultrasonographic parameters | ||||||
IMT (mm) | 1.48 (1.27, 1.72) | 1.21 (1.08, 1.37) | <0.001 | 1.44 (1.22, 1.66) | 1.28 (1.13, 1.46) | <0.001 |
MWSS (Pa) | 0.96 (0.80, 1.10) | 1.39 (1.32, 1.50) | <0.001 | 0.98 (0.78, 1.16) | 1.30 (1.14, 1.48) | <0.001 |
PWSS (Pa) | 1.67 (1.42, 1.99) | 2.21 (1.91, 2.50) | <0.001 | 1.65 (1.41, 1.90) | 2.39 (2.24, 2.54) | <0.001 |
Renal function parameters | ||||||
eGFR (mL·min−1·1.73 m−2) | 89.7 (84.3, 96.7) | 95.1 (86.8, 103.0) | <0.001 | 89.7 (84.4, 97.1) | 94.1 (86.4, 102.1) | <0.001 |
ACR (mg/g) | 15.12 (9.86, 20.35) | 11.45 (8.91, 15.49) | <0.001 | 14.82 (9.91, 20.00) | 11.76 (8.91, 16.21) | <0.001 |